Building Investor-Ready CMC Programs: Marta Kijanka’s Strategic Framework for Early-Stage Biotechs
Description
“CDMOs are partners with deep, extensive technical expertise that can be leveraged strategically—not just a restaurant where you pick from a menu.”
Marta Kijanka, founder of MK Bioconsultancy, is a strategic project manager and CMC consultant who guides early-stage biotech companies through the complexities of manufacturing development, from discovery through regulatory readiness. With her career spanning academia, biotech leadership, CDMO operations, and now strategic consulting, Marta brings a 360-degree perspective to one of the industry’s most critical partnerships.
In the latest PharmaSource podcast episode, Marta explains why successful CMC programs require more than technical competence. She shares frameworks for building productive CDMO partnerships, avoiding common analytical bottlenecks, and creating alignment between scientific, operational, and business teams. Her insights are particularly valuable for companies preparing for Phase 1 and Phase 2 trials, where CMC planning directly impacts investor confidence and valuation.
![[Exclusive] Society of Professional Pharmaceutical Consultants Launches - Interview with Ray Sison](https://s3.castbox.fm/7e/d8/06/985de3dbbde8a4d5fdaf5c7647ab089b8f_scaled_v1_400.jpg "[Exclusive] Society of Professional Pharmaceutical Consultants Launches - Interview with Ray Sison")
United States
